Comparison of Dermaroller versus Dermaroller with topical PRP versus glycolic acid chemical peels in melasma

Not Applicable

• Conditions: Health Condition 1: L818- Other specified disorders of pigmentation

• Registration Number: CTRI/2021/03/031705
• Lead Sponsor: Dr Surabhi Dayal

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Patients of melasma of epidermal variety (differentiated by Woodâ??s lamp examination) with MASI more than 10 who have not taken treatment for melasma for last 4 weeks will be included in the study.

Exclusion Criteria

1. Pregnant and lactating women.

2. Patient with hypersensitivity to formulation used in the study.

3. Patient on any topical and systemic concurrent therapy that can cause facial

melanosis in last 4 weeks.

4. Patient with active or recurrent herpes simplex infection, facial warts and

molluscum contagiosum.

5. Patient with history of or evidence of hypertrophic scar or keloid formation.

6. Women on oral contraceptives and hormonal replacement therapy.

7. Patient with history of photosensitivity.

8. Patient having active dermatoses of atopic, seborrheic or other eczematous

types.

9. Patient on medications such as oral or topical retinoids, 5 Fluorouracil,

Imiquimod.

10. History of corticosteroid therapy in last 4 weeks.

11. History of bleeding disorders or on anticoagulant medications

(warfarin,heparin,aspirin)

12. Severe systemic illness or malignancy

13. Patient with history of diabetes, collagen vascular disease, skin cancer or solar

keratosis.

14. Patient having unrealistic expectations

15. Uncooperative patients

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Decrease in MELASMA AREA and SEVERITY INDEX scoring(MASI) from baseline to the end of therapyTimepoint: 12 weeks

Secondary Outcome Measures

Name	Time	Method
Decrease in MELASMA QUALITY OF LIFE scoring (MELASQOL scoring) from baseline to the end of therapyTimepoint: 12 weeks